Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Ugandan officials are preparing to deploy a trial vaccine as part of efforts to stem an outbreak of Ebola in the capital, ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a ...

Fortress Biotech, Helocyte have announced the dosing of the first subject in the trial of Triplex for individuals who are ...

Fortress Biotech (NASDAQ:FBIO)'s Chairman and CEO, Dr. Lindsay (NYSE:LNN) A. Rosenwald, expressed optimism about the vaccine's role in preventing and treating CMV in the future. While analysts ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

SHELTON, CT / / January 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Phase I trials are conducted to provide initial indications ... Here the authors report an optimized self-replicating RNA (srRNA) vaccine approach that generates protective immunity at much ...